DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Here's Why DexCom (DXCM) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom (DXCM) to Launch Latest CGM System G7 in Canada
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $94.55, marking a +1.34% move from the previous day.
Buy this Tech Stock on the Dip in October for 50% Upside?
by Benjamin Rains
DXCM stock is currently down over 40% from its 2021 highs and trading 51% below its average Zacks price target even though it stands out in the connected health world that's likely to become standard medical practice.
Dynatronics Corporation (DYNT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -85.29% and 5.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring
by Zacks Equity Research
DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.
Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOT
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $94.16 in the latest trading session, marking a -1.19% move from the prior day.
Should Vanguard Mid-Cap ETF (VO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VO
DexCom (DXCM) Launches Latest CGM Sensor ONE in France
by Zacks Equity Research
DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.
Here's Why You Should Retain DexCom (DXCM) Stock for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $105.22, moving +0.34% from the previous trading session.
DexCom (DXCM) Rises 7% in One Week: What's Driving It?
by Zacks Equity Research
DexCom's (DXCM) shares have rallied nearly 7% over the past week, presumably on positive outlook for its CGM devices amid rising competition.
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $104.91, moving -1.84% from the previous trading session.
Strength Seen in DexCom (DXCM): Can Its 6.5% Jump Turn into More Strength?
by Zacks Equity Research
DexCom (DXCM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany
by Zacks Equity Research
DexCom's (DXCM) G6 CGM system and Omnipod 5 AID system can now simplify diabetes management and improve health outcomes in Germany.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $101.90, marking a +0.91% move from the previous day.
Is Trending Stock DexCom, Inc. (DXCM) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to DexCom (DXCM). This makes it worthwhile to examine what the stock has in store.
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of a solid foundation for innovative therapies.
Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test
by Zacks Equity Research
Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.
Is Caribou Biosciences (CRBU) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Caribou Biosciences, Inc. (CRBU) and DexCom (DXCM) have performed compared to their sector so far this year.
Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport
by Zacks Equity Research
Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and acquisitions.